AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$MDGL

Sibold William John sold $6.2M of MDGL

Sibold William John (President and CEO) sold 11,583 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $538.65 ($527.88–$546.38, $6.24M total) across 24 trades over 2026-09-09 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sibold William John
Published Sep 11, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MDGL
Bearish
medium confidence
Mentioned
$MDGL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLBearishLow
01

Why it matters

Provides fresh data on insider sentiment for MDGL.

02

Market read

First public disclosure of a multi‑million insider sell; modest relevance for traders monitoring MDGL.

03

What to watch

CEO may be diversifying holdings; 10b5‑1 plans can mask timing motives.

Relevance 5/10Novelty 5/10Timing: after‑hours filing on Sep 11

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$MDGLBearishMedium confidence
Context

CEO William John Sibold sold $6.2M of MDGL shares via a 10b5‑1 plan, reducing his stake to 197,746 shares.

Expected impact

Potential modest downside of 2‑4% if market interprets as lack of confidence.

Evidence & confidence

Sale size is moderate and executed under a pre‑arranged plan, limiting immediate signal strength.

Market effects

Sector

Biotech sector may see slight caution as insider activity is monitored.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Sale could be routine liquidity management, not a negative signal.

Key entities

  • Company
    Madrigal Pharmaceuticals, Inc.

    Biotech firm developing therapies for metabolic diseases.

  • Executive
    William John Sibold

    President and CEO of MDGL.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MDGL insider trading history →

Related articles

JUL 30
$MDGLMed

MADRIGAL PHARMACEUTICALS, INC. (MDGL): Results of Operations and Financial Condition

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% • As of June 30, 2026, more than 49,000 patient

SEC EDGAR 8-K6 min
SEP 17
$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 26,990 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.79 ($542.78–$564.46, $14.92M total) across 22 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min